EVERY WOMEN EVERY CHILD UN COMMISSION ON LIFE-âSAVING

More documents

Recommendations

Info

integrated. There will be an integrated LMIS and inventory management assessment, an integrated forecasting and quantification capacity building exercise. The review of the essential medicines list will be carried out after two years since the last review took place in 2012. 3.1 Reproductive Health Commodities 3.1.1 Female Condom Problem statement The problem with female condoms is that the product is not widely known among potential clients and the market is still small. Uganda introduced Female condoms in the public sector in 2006 but the majority expired in stock. A pilot re-‐introduction of the female condoms commenced in 2009 with 200,000 female condoms in specific communities with a focus on most at risk populations. Information on female condom use /needs is also not included in Government Health Information Systems, neither is it on the NMS catalogue, order form, and in the national forecast and quantification process). Specific issues identified Provider issues: There is inadequate supply of female condoms at service level and lack of training and knowledge among service providers. Formulation/ market shaping: Limited varieties and market is very small hence less incentive for the private sector Evidence/ regulatory issues: There is lack of comprehensive national female condom implementation strategy and inadequate of post testing capacity at National Drug Authority. Product development/ market shaping: Limited varieties and market is very small hence less incentive for the private sector Awareness/ demand There lack of knowledge and widespread misconceptions about the condom (perceived as meant for prostitutes) and inadequate promotion of female condom Implementation plan a) Immediate plan
Popularize the female condom through demonstrations and awareness building. To do this dummies and equipment for demonstration of female condom use and IEC materials will be procured and distributed. This will be supported by media awareness on female condoms and expulsion of rumors and misconceptions about the female condom. Demand creation through social marketing and condomize female condom campaign will be done. A knowledge, attitudes and practices (KAP) study will be conducted to inform this process. b) Intermediate plan • Develop, print and disseminate a national female condom implementation strategy. Build capacity for post shipment testing at national level (Procure laboratory equipment for female condom testing, Acquire technical experts on ISO certification process, build internal capacity for the NDA staff) and track shipments in to the country through the RHInterchange. • Strengthen national forecasting and quantification of female condoms and implement the alternative distribution plan. Integrate female condoms into the public sector supply chain, information in the national HMIS and develop social marketing channels, introduce a voucher system for public sector and private sector and use of mobile phones for tracking stock status at service delivery points. 3.1.2 Contraceptive Implants Problem statement Implants are an effective, safe and user-‐friendly method of family planning that has the potential to widen choices that are currently available. Widening method mix supports higher overall contraceptive uptake and continuation. Specific issues identified Provider issues: A large proportion of service providers are not trained in insertion and removal. Paramedical workers not allowed by law to insert and remove implants -‐ Revise the policy guidelines to allow trained paramedics to insert and remove implants. Provider bias and limited knowledge on how to manage side effects, poor counseling skills; Continuous bleeding leading to discontinuation of use. Formulation/ market shaping: Limited varieties and market is very small hence less incentive for the private sector Evidence/ regulatory issues: There is minimal capacity to test quality of implants and register additional suppliers for Uganda. Inadequate post testing capacity at National Drug Authority, including inability to carryout post market surveys to determine quality of implants.
Page 2 and 3: 1. BACKGROUND ...................
Page 4 and 5: 1. BACKGROUND 1.1 Introduction The
Page 6 and 7: RMNCH services and commodities
Page 8 and 9: 1.3 Process of development of
Page 12 and 13: Product development/ market shap
Page 15: community level. However the po
Page 20 and 21: Specific issues identified Provid
Page 22 and 23: A parallel step will be to im
Page 24 and 25: inefficiencies and sustainability
Page 26 and 27: 3.4.2 Amoxicillin tablets for tr
Page 28 and 29: progressively achieve national c
Page 30: REFERENCES 1. Annual Health Secto

EVERY WOMEN EVERY CHILD UN COMMISSION ON LIFE-âSAVING

Create successful ePaper yourself

Delete template?

Save as template?

EVERY WOMEN EVERY CHILD UN COMMISSION ON LIFE-âSAVING